>>"Based on prevailing estimates, there are approximately 80,000 people in the European Union and 60,000 people in the US with HD. " Still don't understand why, with this prevalence, they allow such small trials for approval purposes?<<
The European and U.S. ATryn trials test individuals with HD who undergo elective surgery or childbirth. Only a small fraction of the 60-80K patient pool will have such a procedure scheduled during any given time period.
Market Data 
Markets 
AI
